JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
JW (Cayman) Therapeutics Co. Ltd. has announced a change in its auditor, with Deloitte Touche Tohmatsu replacing PricewaterhouseCoopers due to a disagreement over audit fees. The transition to Deloitte is expected to maintain audit quality without disrupting the company’s financial reporting for the year ending December 31, 2024. This strategic move underscores the company’s commitment to aligning with industry standards and ensuring shareholder interests.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.